Author

Maartje Mangelaars

Institution: Johnson & Johnson (Netherlands)

Observed institution: Johnson & Johnson (Netherlands)

ORCID: 0009-0002-7081-6892

Observed ORCID: 0009-0002-7081-6892

OpenAlex ID: A5147861914

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

2023 · Franz Koenig, Cécile Spiertz, et al. · EClinicalMedicine · 48

Maternal health, neonatology and perinatology towards a standardized outcome set for clinical trials in Hemolytic Disease of the Fetus and Newborn (HDFN): preliminary findings from two European advisory boards

2026 · Enrico Lopriore, Maartje Mangelaars, et al. · Maternal Health Neonatology and Perinatology

Patient perspectives from the BEYOND Delphi panel: burden of remaining symptoms and their fluctuations, despite treatment, in patients with generalised myasthenia gravis

2026 · Sophie Lehnerer, Maria Bonaria Uccheddu, et al. · BMC Neurology

Understanding the Lived Experience of Fetal and Neonatal Alloimmune Thrombocytopenia: A Qualitative Study

2026 · Ellen Elisabeth Johanna de Kreij, Melanie Mesch, et al. · American Journal of Perinatology Reports

Insights on the Lived Experience of Warm Autoimmune Hemolytic Anemia (wAIHA) from an Ongoing Patient Council

2024 · Merel Güttinger, Karen A Jones, et al. · Blood

Works count: 5

Citation count: 48

H-index: 1

I10-index: 1